

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

COLLABORATION AND LICENSE AGREEMENT FOR TRANSEPTAL MITRAL VALVE REPLACEMENT WITH HIGHLIFE SAS

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on December 18, 2020, the Company entered into a license agreement (the “**License Agreement**”, or “**Agreement**”) with HighLife SAS (“**HighLife**” or the “**Licensor**”), a France-based medical device company, pursuant to which HighLife has granted to the Company an exclusive license regarding certain proprietary Transcatheter Mitral Valve Replacement (“**TMVR**”) products (the “**Products**”) currently under development by the Licensor. Pursuant to the Agreement, the Company is entitled to, among other things, manufacture, develop, and commercialize the Products in the Greater China region, and HighLife is in return entitled to receive an upfront license fee and subsequent milestone payments.

The Products developed by HighLife use a transeptal approach to treat patients with mitral valve regurgitation, and are currently in clinical studies in more than 20 sites around the globe. The Company views the collaboration as an important step to strengthen its structural heart pipeline by adding potentially first-in-class clinical-stage TMVR products, and hopes to benefit more patients by expanding the Products’ presence in the Greater China region.

To the best knowledge of the Company, the transactions contemplated under the License Agreement do not constitute notifiable transactions or connected transactions of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, December 21, 2020

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wayne Wu and Mr. Wai Ming Yip as independent non-executive Directors.